PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 4, 2026Vaccines0 citationsOpen Access

Data-Driven Vaccine Clinical Trial Design Features and Associated Progress Patterns: An Analysis of 1618 Clinical Trials from 2012 to 2022

View Full Paper
SCS. H. ChanDZDachuang ZhouDZDi Zhang

Key Points

  • This study aims to connect vaccine trial design features to progression outcomes and identify favorable configurations.
  • Analyzed 1618 vaccine trials registered from 2012 to 2022.
  • Used logistic regression to assess associations with progression and random forest classifiers for probability estimation.
  • Conducted Monte Carlo simulations to compare robust configurations with random designs.
  • 579 of 1618 trials (35.8%) achieved phase progressions.
  • Factors like larger sample sizes and COVID-19 indications were linked to higher odds of progression.
  • Model-identified configurations showed a 24.1% increase in predicted progression probability compared to historical designs.

Abstract

Background/Objectives: Vaccine clinical trials face high costs, long timelines, and variable progression rates, yet systematic evidence linking trial design features to progression outcomes remains limited. This study aimed to identify trial design features associated with vaccine trial progression and to explore robust design configurations using machine learning approaches. Methods: We analyzed 1618 vaccine trials registered from 2012 to 2022. Progression was defined as phase advancement (phase I/II) or regulatory authorization (phase III). Logistic regression assessed associations with progression. Random forest classifiers with cross-validation were used to estimate predicted progression probabilities based on combinations of design features. Monte Carlo simulations compared model-identified robust configurations with randomly generated configurations. Results: Among 1618 trials, 579 achieved phase progressions, corresponding to an overall observed progression rate of 35.8%. Larger sample size, preventive vaccine purpose, COVID-19 indication, and enrollment across all age groups were consistently associated with higher observed odds of progression in both univariable and multivariable logistic regression analyses. In machine learning analyses, the pooled mean predicted progression probability of model-identified robust configurations was 48.93%, compared with 39.44% for historically observed design configurations, corresponding to a relative increase of 24.1%. Simulations further showed a lower projected cumulative development duration (106.87 vs. 128.25 months; −16.7%) and reduced projected cost (USD 100.67M vs. USD 108.33M; −7.1%) for robust configurations compared with historical strategies. Conclusions: This study provides a data-driven framework for characterizing historical vaccine trial design patterns. By integrating machine learning with observational registry data, it supports hypothesis generation and descriptive benchmarking of design features that may inform the design of future prospective or causal investigations.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chan et al. (2026) studied this question.

synapsesocial.com/papers/6a2117bfd499ed480b1708d7https://doi.org/10.3390/vaccines14060489
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Novel Model Using ML Techniques for Clinical Trial Design and Expedited Patient Onboarding Process2025 · 5 citations
  2. 2Clinical Trial Termination or Withdrawal in Head and Neck Squamous Cell Carcinoma2026 · 4 citations
  3. 3Using Bayesian pre-trial simulations to optimize the design of adaptive clinical trials in childhood nephrotic syndrome2025 · 6 citations
  4. 4Estimation of clinical trial success rates and related parameters2017 · 1,583 citations
  5. 5Leveraging Data Science for Global Health2020 · 39 citations